United States: The US FDA has suggested a new rule for testing talc for asbestos in cosmetics which are still used by consumers everyday since talc has been identified as a confirmed human carcinogen. Asbestos causes lung and ovarian cancer diseases among humans, as reported by HealthDay.
Specific Detection Procedures for Talc Products
FDA proposes new tests to detect asbestos in cosmetics and other products containing talc https://t.co/oRt5TwM3mR
— CBSColorado (@CBSNewsColorado) December 27, 2024
Examination of each batch of talc-based cosmetic products will be carried out under plain light microscopy, polarizing light microscopy, and transmission electron microscopy in compliance with the proposed rule. The enforcement of these standards will automatically make the products bearing default in the Federal Food, Drug, and Cosmetic Act.
Longstanding Issue with Asbestos in Talc Cosmetics
Proposed FDA Rule Targets Asbestos in Talc Cosmetic Products https://t.co/FyakHXtsGJ
— Drugs.com (@Drugscom) December 27, 2024
The fact that talc-produced cosmetics contain asbestos has been existent for many years. With such acknowledgment, the FDA noted that asbestos is a human carcinogen and recommended that there should be an acceptable exposure level to it The proposed rule is to eliminate it in order to protect the consumer health.
Johnson & Johnson’s dealing with legal headaches
New FDA proposal to mandate rigorous testing in cosmetics industry! It's time to ensure that talc in our products is asbestos-free. Stay informed: https://t.co/Ece7zU8sDy
— KFDM News (@kfdmnews) December 27, 2024
This decision was made after Johnson & Johnson reported over 60,000 cases that involved people who alleged that the company’s baby powder contain asbestos which cause cancer. Despite its denials of these allegations, it is handling these lawsuits via a $10 billion settlement in the bankruptcy court, as reported by HealthDay.
Public and Industry Feedback Period
FDA proposes new talc testing rules to keep cosmetics asbestos-free | Watch full video at https://t.co/Fd46VPvuyg
— Bobby Buckles (Rob) (@bobby_buckles) December 27, 2024
The FDA’s proposal is now open for public and industry feedback for 90 days. Once this period concludes, the rule will move toward its final stage.